๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Pemetrexed

Also listed in trial records as Cetuximab, Daraxonrasib, Only, Alimta, Erbitux, C225
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 235 trials in our China, USA, UK, India and Ireland registers that name Pemetrexed as an intervention. Synced 24 Sep 2026
235Trials tracked
125Recruiting now
113Lead sponsors
5Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards

Pemetrexed is named as a drug or biological intervention in 235 clinical trials in our China, USA, UK, India and Ireland trial registers, 125 of which are recruiting. Lead sponsors include AstraZeneca (22), Merck Sharp & Dohme LLC (19) and Bristol-Myers Squibb (12). Registered phases: Phase 3, Phase 2, Phase 1, Phase 1/2, Phase 2/3, Observational, Not applicable and Phase 4. Conditions studied include Non-Small Cell Lung Cancer; Non-small Cell Lung Cancer; NSCLC.

01

Clinical trials of Pemetrexed

235 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT07092202 Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases (ClinicalTrials.gov ↗)
Leptomeningeal Metastasis, NSCLC, Intrathecal Chemotherapy
 Phase 4 Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology China
NCT04892173 JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC (ClinicalTrials.gov ↗)
Carcinoma, Squamous Cell
 Phase 3 Recruiting Johnson & Johnson Enterprise Innovation Inc. UK, USA, India, China
NCT05055908 Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors (ClinicalTrials.gov ↗)
Lung Cancer
 Phase 3 Recruiting Hunan Province Tumor Hospital China
NCT05253651 A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Colorectal Neoplasms
 Phase 3 Recruiting Seagen, a wholly owned subsidiary of Pfizer Ireland, UK, USA, China
NCT05751512 A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN (ClinicalTrials.gov ↗)
Squamous Cell Carcinoma of the Head and Neck
 Phase 3 Recruiting Lepu Biopharma Co., Ltd. China
NCT06064877 A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma (ClinicalTrials.gov ↗)
Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
 Phase 3 Recruiting AVEO Pharmaceuticals, Inc. UK, USA, China
NCT06119581 A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (ClinicalTrials.gov ↗)
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
 Phase 3 Recruiting Eli Lilly and Company UK, USA, India, China
NCT06312137 A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (ClinicalTrials.gov ↗)
Non Small Cell Lung Cancer
 Phase 3 Recruiting Merck Sharp & Dohme LLC UK, USA, China
NCT06417814 A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (ClinicalTrials.gov ↗)
Metastatic Non-small Cell Lung Cancer
 Phase 3 Recruiting AstraZeneca UK, USA, India, China
NCT06452277 A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) (ClinicalTrials.gov ↗)
Advanced Non-small Cell Lung Cancer, HER2 Mutation
 Phase 3 Recruiting Bayer UK, USA, China
NCT06561386 A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression โ‰ฅ 1%
Non-small Cell Lung Cancer
 Phase 3 Recruiting Bristol-Myers Squibb Ireland, UK, USA, India, China
NCT06623422 A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Carcinoma, Non-Small-Cell Lung
 Phase 3 Recruiting Merck Sharp & Dohme LLC Ireland, UK, USA, China
NCT06627647 A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC (ClinicalTrials.gov ↗)
Non-squamous Non-small Cell Lung Cancer
 Phase 3 Recruiting AstraZeneca UK, USA, India, China
NCT06662786 A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Colorectal Neoplasms
 Phase 3 Recruiting Janssen Research & Development, LLC UK, USA, India, China
NCT06750094 A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Colorectal Neoplasms
 Phase 3 Recruiting Janssen Research & Development, LLC UK, USA, India, China
NCT06754644 A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC (ClinicalTrials.gov ↗)
NSCLC
 Phase 3 Recruiting Qilu Pharmaceutical Co., Ltd. China
NCT06793215 A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (ClinicalTrials.gov ↗)
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
 Phase 3 Recruiting Hoffmann-La Roche Ireland, UK, USA, China
NCT06829459 A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs (ClinicalTrials.gov ↗)
Non-Small Cell Lung Cancer
 Phase 3 Recruiting Shanghai JMT-Bio Inc. China
NCT06875310 A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) (ClinicalTrials.gov ↗)
Carcinoma, Non-Small-Cell Lung
 Phase 3 Recruiting Mirati Therapeutics Inc. Ireland, UK, USA, India, China
NCT06881784 Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) (ClinicalTrials.gov ↗)
NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC
 Phase 3 Recruiting Revolution Medicines, Inc. Ireland, UK, USA
NCT06899126 Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
 Phase 3 Recruiting Daiichi Sankyo UK, USA, India, China
NCT06927986 Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC๏ผˆSYNSTAR01๏ผ‰ (ClinicalTrials.gov ↗)
EGFR-mutated Locally Advanced or Metastatic NSCLC
 Phase 3 Recruiting CSPC Megalith Biopharmaceutical Co.,Ltd. China
NCT06997497 A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) (ClinicalTrials.gov ↗)
Colon Adenocarcinoma, Rectal Adenocarcinoma
 Phase 3 Recruiting Merck Sharp & Dohme LLC UK, USA, China
NCT07109531 ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy (ClinicalTrials.gov ↗)
Locally Advanced or Metastatic NSCLC
 Phase 3 Recruiting Jiangsu Aosaikang Pharmaceutical Co., Ltd. China
NCT07190248 A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Non-small Cell Lung Cancer
 Phase 3 Recruiting Merck Sharp & Dohme LLC UK, USA, China
NCT07252232 Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) (ClinicalTrials.gov ↗)
Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
 Phase 3 Recruiting Revolution Medicines, Inc. UK, USA
NCT07491445 Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma (ClinicalTrials.gov ↗)
Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC
 Phase 3 Recruiting Revolution Medicines, Inc. UK, USA, China
NCT07549399 SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC (ClinicalTrials.gov ↗)
Rectal Adenocarcinoma, High-Risk Cancer, MSS
 Phase 3 Recruiting Sixth Affiliated Hospital, Sun Yat-sen University China
NCT07702032 Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1) (ClinicalTrials.gov ↗)
Left-sided Colorectal Cancer
 Phase 3 Recruiting Genmab USA
NCT07777822 Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC (ClinicalTrials.gov ↗)
NSCLC, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer NSCLC
 Phase 3 Recruiting Revolution Medicines, Inc. USA
NCT07805954 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC
 Phase 3 Recruiting Revolution Medicines, Inc. USA
NCT06236438 Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (ClinicalTrials.gov ↗)
Non-Small Cell Lung Cancer
 Phase 2/3 Recruiting AbbVie USA
NCT06712316 Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ClinicalTrials.gov ↗)
Non-small Cell Lung Cancer
 Phase 2/3 Recruiting BioNTech SE UK, USA, China
NCT07005102 A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer (ClinicalTrials.gov ↗)
Non-Squamous Non-Small Cell Lung Cancer
 Phase 2/3 Recruiting AbbVie USA, China
NCT07063745 A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion (ClinicalTrials.gov ↗)
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
 Phase 2/3 Recruiting Bristol-Myers Squibb UK, USA, India, China
NCT07100080 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Non-Small Cell Lung Cancer
 Phase 2/3 Recruiting Bristol-Myers Squibb UK, USA, India, China
NCT07365319 A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. (ClinicalTrials.gov ↗)
Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC
 Phase 2/3 Recruiting Eikon Therapeutics USA
NCT07642024 A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09) (ClinicalTrials.gov ↗)
Non-small Cell Lung Cancer
 Phase 2/3 Recruiting Sichuan Baili Pharmaceutical Co., Ltd. China
NCT07662395 SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer (ClinicalTrials.gov ↗)
Double Blind
 Phase 2/3 Recruiting Sinocelltech Ltd. China
NCT03899155 Pan Tumor Rollover Study
Cancer
 Phase 2 Recruiting Bristol-Myers Squibb Ireland, UK, USA, China
NCT05260671 Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN (ClinicalTrials.gov ↗)
Head and Neck Neoplasms, Recurrent Disease, Metastatic Cancer
 Phase 2 Recruiting Eye & ENT Hospital of Fudan University China
NCT05498428 A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (ClinicalTrials.gov ↗)
Carcinoma, Non-small-Cell Lung
 Phase 2 Recruiting Janssen Research & Development, LLC UK, USA, China
NCT05628038 The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer (ClinicalTrials.gov ↗)
Recurrent Rectal Cancer
 Phase 2 Recruiting Fudan University China
NCT05766800 Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer (ClinicalTrials.gov ↗)
Locally Advanced, Non-small Cell Lung Cancer
 Phase 2 Recruiting Shanghai Pulmonary Hospital, Shanghai, China China
NCT06001151 Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative (ClinicalTrials.gov ↗)
Carcinoma, Non-Small-Cell Lung
 Phase 2 Recruiting Qian Chu China
NCT06296745 Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib. (ClinicalTrials.gov ↗)
Leptomeningeal Metastasis
 Phase 2 Recruiting Guangzhou Medical University China
NCT06306846 Neoadjuvant SBRT in Localized Advanced HNSCC (ClinicalTrials.gov ↗)
Head and Neck Squamous Carcinoma
 Phase 2 Recruiting Jiang Feng China
NCT06540326 Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab (ClinicalTrials.gov ↗)
Colorectal Cancer Metastatic
 Phase 2 Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine China
NCT06547203 Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study (ClinicalTrials.gov ↗)
Colorectal Cancer Metastatic
 Phase 2 Recruiting Sun Yat-sen University China
NCT06590259 A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM (ClinicalTrials.gov ↗)
Colorectal Cancer Liver Metastasis
 Phase 2 Recruiting Shanghai 6th People's Hospital China
NCT06603376 Irinotecan Hydrochloride Liposome Injection (โ…ก) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer (ClinicalTrials.gov ↗)
Colorectal Carcinoma
 Phase 2 Recruiting Shanghai Changzheng Hospital China
NCT06731907 A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) (ClinicalTrials.gov ↗)
Non-small Cell Lung Cancer
 Phase 2 Recruiting Merck Sharp & Dohme LLC USA
NCT06788912 Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) (ClinicalTrials.gov ↗)
Lung Neoplasm Malignant
 Phase 2 Recruiting Merck Sharp & Dohme LLC USA
NCT06868836 Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy (ClinicalTrials.gov ↗)
Non-squamous Non-small Cell Lung Cancer
 Phase 2 Recruiting Shanghai Junshi Bioscience Co., Ltd. China
NCT06935188 Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC (ClinicalTrials.gov ↗)
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
 Phase 2 Recruiting Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University China
NCT06978829 Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC (ClinicalTrials.gov ↗)
LA HNSCC
 Phase 2 Recruiting Daping Hospital and the Research Institute of Surgery of the Third Military Medical University China
NCT07181499 Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI (ClinicalTrials.gov ↗)
NSCLC, Adjuvant Drug Therapy, EGFR
 Phase 2 Recruiting Betta Pharmaceuticals Co., Ltd. China
NCT07209111 A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) (ClinicalTrials.gov ↗)
Neoplasm Malignant
 Phase 2 Recruiting Merck Sharp & Dohme LLC UK, USA, China
NCT07252739 KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) (ClinicalTrials.gov ↗)
Malignant Neoplasm
 Phase 2 Recruiting Merck Sharp & Dohme LLC USA, China
NCT07415031 A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies (ClinicalTrials.gov ↗)
Solid Tumors
 Phase 2 Recruiting Mirati Therapeutics Inc. UK, USA, China
NCT07474727 A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer (ClinicalTrials.gov ↗)
Colorectal Cancer
 Phase 2 Recruiting Multitude Therapeutics Inc. China
NCT07486817 Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab (ClinicalTrials.gov ↗)
Lung Cancer, Non-squamous, Non-small Cell
 Phase 2 Recruiting Boehringer Ingelheim China
NCT07492680 A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Solid Tumors
 Phase 2 Recruiting Bristol-Myers Squibb Ireland, USA, China
NCT07506109 A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer (ClinicalTrials.gov ↗)
BRAF V600E, Colorectal Cancer, Sintilimab
 Phase 2 Recruiting Tianjin Medical University Cancer Institute and Hospital China
NCT07586202 A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC (ClinicalTrials.gov ↗)
Carcinoma, Non-Small-Cell Lung
 Phase 2 Recruiting Janssen Research & Development, LLC USA, China
NCT07644559 A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer (ClinicalTrials.gov ↗)
Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS
 Phase 2 Recruiting Verastem, Inc. USA
NCT07659795 A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer (ClinicalTrials.gov ↗)
Colorectal Cancer
 Phase 2 Recruiting Verastem, Inc. USA
NCT07680764 A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
 Phase 2 Recruiting Bristol-Myers Squibb UK, USA, China
NCT07722754 Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial (ClinicalTrials.gov ↗)
Colorectal Neoplasms Malignant, Neoplasm, Metastatic
 Phase 2 Recruiting Guangdong Provincial People's Hospital China
NCT04165070 KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naรฏve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) (ClinicalTrials.gov ↗)
Carcinoma, Non-Small-Cell Lung
 Phase 1/2 Recruiting Merck Sharp & Dohme LLC USA
NCT04198766 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytrudaยฎ) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (ClinicalTrials.gov ↗)
Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer
 Phase 1/2 Recruiting Inhibrx Biosciences, Inc USA
NCT05098132 Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC
 Phase 1/2 Recruiting Synthekine Ireland, USA
NCT05410145 A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation (ClinicalTrials.gov ↗)
KRAS P.G12C
 Phase 1/2 Recruiting D3 Bio (Wuxi) Co., Ltd USA, China
NCT05431270 Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) (ClinicalTrials.gov ↗)
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
 Phase 1/2 Recruiting Phanes Therapeutics USA
NCT05443126 A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies (ClinicalTrials.gov ↗)
NSCLC
 Phase 1/2 Recruiting Ellipses Pharma UK, USA
NCT05584670 A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Solid Tumor
 Phase 1/2 Recruiting Sanofi USA
NCT05786924 Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies (ClinicalTrials.gov ↗)
Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis
 Phase 1/2 Recruiting Institut de Recherches Internationales Servier China
NCT05789082 A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation (ClinicalTrials.gov ↗)
Non-Small Cell Lung Cancer
 Phase 1/2 Recruiting Hoffmann-La Roche UK, USA, China
NCT06128551 Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors (ClinicalTrials.gov ↗)
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
 Phase 1/2 Recruiting Revolution Medicines, Inc. USA
NCT06162221 Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC (ClinicalTrials.gov ↗)
Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer
 Phase 1/2 Recruiting Revolution Medicines, Inc. USA
NCT06445062 Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors (ClinicalTrials.gov ↗)
Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma
 Phase 1/2 Recruiting Revolution Medicines, Inc. USA
NCT06462092 Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer (ClinicalTrials.gov ↗)
Leptomeningeal Metastases
 Phase 1/2 Recruiting Guangzhou Medical University China
NCT06741644 A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
Advanced Solid Tumors
 Phase 1/2 Recruiting CStone Pharmaceuticals USA, China
NCT06772623 Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations (ClinicalTrials.gov ↗)
Non Small Cell Lung Carcinoma
 Phase 1/2 Recruiting AbbVie UK, USA, China
NCT06809517 Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis
Leptomeningeal Metastasis, Intrathecal Drug Delivery
 Phase 1/2 Recruiting Guangzhou Medical University China
NCT06943820 AK129 Combination Therapy for Advanced Solid Tumors (ClinicalTrials.gov ↗)
Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma
 Phase 1/2 Recruiting Akeso China
NCT06996782 A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Advanced or Metastatic Non-small Cell Lung Cancer
 Phase 1/2 Recruiting AstraZeneca USA, China
NCT07012954 ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC (ClinicalTrials.gov ↗)
Colorectal Cancer Metastatic
 Phase 1/2 Recruiting Sun Yat-sen University China
NCT07020221 A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors (ClinicalTrials.gov ↗)
Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer
 Phase 1/2 Recruiting Verastem, Inc. USA
NCT07059221 A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer (ClinicalTrials.gov ↗)
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
 Phase 1/2 Recruiting Suzhou Suncadia Biopharmaceuticals Co., Ltd. China
NCT07223047 A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies (ClinicalTrials.gov ↗)
Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
 Phase 1/2 Recruiting Bristol-Myers Squibb USA
NCT07286149 A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) (ClinicalTrials.gov ↗)
Lung Neoplasm Malignant
 Phase 1/2 Recruiting Merck Sharp & Dohme LLC USA, China
NCT07397338 Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors (ClinicalTrials.gov ↗)
Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC)
 Phase 1/2 Recruiting Revolution Medicines, Inc. USA
NCT07468071 Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments (ClinicalTrials.gov ↗)
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
 Phase 1/2 Recruiting Novartis Pharmaceuticals China
NCT07790510 HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer (ClinicalTrials.gov ↗)
Metastatic Colorectal Cancer (CRC)
 Phase 1/2 Recruiting Haisco Pharmaceutical Group Co., Ltd. China
NCT03715933 Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas (ClinicalTrials.gov ↗)
Ewing Sarcoma, Colorectal Adenocarcinoma
 Phase 1 Recruiting Inhibrx Biosciences, Inc UK, USA
NCT04686305 Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC (ClinicalTrials.gov ↗)
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
 Phase 1 Recruiting AstraZeneca USA, China
NCT04929223 A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (ClinicalTrials.gov ↗)
Metastatic Colorectal Cancer
 Phase 1 Recruiting Hoffmann-La Roche UK, USA
NCT05067283 A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
Advanced Solid Tumors
 Phase 1 Recruiting Merck Sharp & Dohme LLC USA, China
NCT05382559 A Study of ASP3082 in Adults With Advanced Solid Tumors (ClinicalTrials.gov ↗)
Solid Tumor
 Phase 1 Recruiting Astellas Pharma Inc USA, China
NCT05836324 A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors (ClinicalTrials.gov ↗)
Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
 Phase 1 Recruiting Incyte Corporation UK, USA, China
NCT06179160 A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Solid Tumors
 Phase 1 Recruiting Incyte Corporation USA
NCT06241456 FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Advanced Solid Tumor
 Phase 1 Recruiting Fate Therapeutics USA
NCT06332170 ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors (ClinicalTrials.gov ↗)
Advanced Solid Tumor
 Phase 1 Recruiting Hansoh BioMedical R&D Company China
NCT06384352 Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors (ClinicalTrials.gov ↗)
Advanced Solid Tumors
 Phase 1 Recruiting MediLink Therapeutics (Suzhou) Co., Ltd. USA, China
NCT06551142 A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) (ClinicalTrials.gov ↗)
Neoplasms
 Phase 1 Recruiting GlaxoSmithKline UK, USA
NCT06561685 A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer
 Phase 1 Recruiting Eli Lilly and Company USA
NCT06586515 MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
 Phase 1 Recruiting Eli Lilly and Company Ireland, USA, China
NCT06720987 A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
KRAS G12C Mutation, KRAS G12S Mutation, Solid Tumor Malignancies
 Phase 1 Recruiting Kumquat Biosciences Inc. USA
NCT06764771 A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors (ClinicalTrials.gov ↗)
Advanced Malignant Tumors
 Phase 1 Recruiting Bristol-Myers Squibb USA
NCT06797336 A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors
Solid Tumor
 Phase 1 Recruiting PAQ Therapeutics, Inc. USA
NCT06835569 A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations (ClinicalTrials.gov ↗)
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer)
 Phase 1 Recruiting Alterome Therapeutics, Inc. USA
NCT06917079 BBO-11818 in Adult Subjects With KRAS Mutant Cancer (ClinicalTrials.gov ↗)
Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma
 Phase 1 Recruiting TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) USA
NCT06969612 A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC (ClinicalTrials.gov ↗)
NSCLC (Advanced Non-small Cell Lung Cancer)
 Phase 1 Recruiting Peking University Cancer Hospital & Institute China
NCT07030959 Study of AUBE00 in Patients With Solid Tumors (ClinicalTrials.gov ↗)
Solid Tumors
 Phase 1 Recruiting Chugai Pharmaceutical USA
NCT07128303 Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors (ClinicalTrials.gov ↗)
Advanced Solid Tumor
 Phase 1 Recruiting Gilead Sciences USA
NCT07216105 FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors (ClinicalTrials.gov ↗)
Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer
 Phase 1 Recruiting Fate Therapeutics USA
NCT07247110 A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) (ClinicalTrials.gov ↗)
Malignant Neoplasm
 Phase 1 Recruiting Merck Sharp & Dohme LLC USA
NCT07300150 A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors (ClinicalTrials.gov ↗)
Colorectal Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer
 Phase 1 Recruiting PAQ Therapeutics, Inc. USA
NCT07318805 A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors (ClinicalTrials.gov ↗)
Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer
 Phase 1 Recruiting Pfizer USA
NCT07349537 Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors (ClinicalTrials.gov ↗)
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma
 Phase 1 Recruiting Revolution Medicines, Inc. USA
NCT07381829 A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer (ClinicalTrials.gov ↗)
Advanced Solid Tumor Cancer
 Phase 1 Recruiting HC Biopharma Inc. China
NCT07813468 A Randomized, Double-Blind, Positive-Controlled, Parallel Pharmacokinetic Phase I Clinical Study of Cetuximab Injection Versus Erbitux in Healthy Male Subjects (ClinicalTrials.gov ↗)
Cetuximab, Bioequivalence, Healthy Volunteers
 Phase 1 Recruiting HC Biopharma Inc. China
NCT06399926 Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir (ClinicalTrials.gov ↗)
Leptomeningeal Metastasis, Lung Cancer
 Observational Recruiting Xiangya Hospital of Central South University China
NCT07751536 ctDNA-driven Adaptive Proton Craniospinal Irradiation in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis After Resistance to Third-Generation TKIs in the Consolidation Phase (ClinicalTrials.gov ↗)
Leptomeningeal Metastasis From Lung Cancer
 Not applicable Recruiting Shuanghu Yuan China
NCT05767892 YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations (ClinicalTrials.gov ↗)
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
 Phase 3 Not yet open Suzhou Puhe Pharmaceutical Technology Co., LTD China
NCT06616259 First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study (ClinicalTrials.gov ↗)
Colorectal Cancer (CRC), Capecitabine, Cetuximab
 Phase 3 Not yet open Meng Qiu China
NCT06704620 Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist๏ผˆDiphenhydramine๏ผ‰in Advanced and Metastatic Non-Small Cell Lung Cancer (ClinicalTrials.gov ↗)
Advanced and Metastatic NSCLC
 Phase 3 Not yet open Tianjin Medical University Cancer Institute and Hospital China
NCT07383116 Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (ClinicalTrials.gov ↗)
Non Squamous Non-small Cell Lung Cancer
 Phase 3 Not yet open Shanghai Huaota Biopharmaceutical Co., Ltd. China
NCT07509099 Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC (ClinicalTrials.gov ↗)
Squamous Cell Carcinoma of Head and Neck
 Phase 3 Not yet open Ji Dongmei China
NCT07680790 Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
Non-Small Cell Lung Cancer
 Phase 3 Not yet open Bristol-Myers Squibb USA, India, China
NCT07768189 A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
Oropharyngeal Carcinoma (OPC)
 Phase 3 Not yet open Corbus Pharmaceuticals Inc. UK, USA
NCT07797153 JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer (ClinicalTrials.gov ↗)
Recurrent or Metastatic Cervical Cancer
 Phase 3 Not yet open Jiangsu Alphamab Biopharmaceuticals Co., Ltd China
NCT07739186 A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) (ClinicalTrials.gov ↗)
Non-squamous Non-small Cell Lung Cancer
 Phase 2/3 Not yet open Sichuan Baili Pharmaceutical Co., Ltd. China
NCT05993858 Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC (ClinicalTrials.gov ↗)
Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
 Phase 2 Not yet open Union Hospital, Tongji Medical College, Huazhong University of Science and Technology China
NCT06441045 Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI (ClinicalTrials.gov ↗)
Leptomeningeal Metastasis
 Phase 2 Not yet open Fujian Cancer Hospital China
NCT06688656 Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC (ClinicalTrials.gov ↗)
Lung Cancer
 Phase 2 Not yet open Shanghai Chest Hospital China
NCT06713057 Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer (ClinicalTrials.gov ↗)
Locally Advanced Thyroid Gland Carcinoma, Thyroid Cancer
 Phase 2 Not yet open West China Hospital China
NCT06861218 Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases (ClinicalTrials.gov ↗)
Leptomeningeal Metastases
 Phase 2 Not yet open Zhejiang Cancer Hospital China
NCT07000305 A Study of Cetuximabฮฒ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer (ClinicalTrials.gov ↗)
Advanced Colorectal Cancer
 Phase 2 Not yet open Tao Zhang China
NCT07070713 Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC (ClinicalTrials.gov ↗)
Metastatic Colorectal Cancer With Left-sided Primary Tumor, Immunotherapy
 Phase 2 Not yet open Fujian Cancer Hospital China
NCT07079410 Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma (ClinicalTrials.gov ↗)
Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma, Resectable Oral and Oropharyngeal Squamous Cell Carcinoma
 Phase 2 Not yet open Shanghai Zhongshan Hospital China
NCT07365410 Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study (ClinicalTrials.gov ↗)
Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Furmonertinib
 Phase 2 Not yet open Tianjin Medical University Cancer Institute and Hospital China
NCT07514793 Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma (ClinicalTrials.gov ↗)
Mesothelioma
 Phase 2 Not yet open Fudan University China
NCT07709585 Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients (ClinicalTrials.gov ↗)
Advanced Non-small Cell Lung Cancer (NSCLC), EGFR Exon 19 Deletion Mutation, EGFR Exon 21 Mutation
 Phase 2 Not yet open Guangzhou University of Traditional Chinese Medicine China
NCT07775040 Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial (ClinicalTrials.gov ↗)
Non-Small Cell Lung Cancer
 Phase 2 Not yet open Sichuan Cancer Hospital and Research Institute China
NCT07678593 A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation (ClinicalTrials.gov ↗)
Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma, RAS Mutation
 Phase 1/2 Not yet open Genfleet Therapeutics (Shanghai) Inc. China
NCT07699757 HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion (ClinicalTrials.gov ↗)
Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC), Advanced Solid Tumors
 Phase 1 Not yet open Haisco Pharmaceutical Group Co., Ltd. China
NCT04762459 Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection (ClinicalTrials.gov ↗)
Non-small Cell Lung Carcinoma
 Phase 3 By invitation Chinese Academy of Medical Sciences China
NCT06281964 Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion. (ClinicalTrials.gov ↗)
Non-Small-Cell Lung Cancer
 Phase 3 By invitation Avistone Biotechnology Co., Ltd. China
NCT07618624 BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression (ClinicalTrials.gov ↗)
Recurrent Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
 Phase 2 By invitation Sun Yat-sen University China
NCT00956007 RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer (ClinicalTrials.gov ↗)
Head and Neck Cancer
 Phase 3 Active, closed Radiation Therapy Oncology Group Ireland, China
NCT02453282 Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) (ClinicalTrials.gov ↗)
Non-Small-Cell Lung Carcinoma NSCLC
 Phase 3 Active, closed AstraZeneca USA
NCT02486718 Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] (ClinicalTrials.gov ↗)
Non-Small Cell Lung Cancer
 Phase 3 Active, closed Hoffmann-La Roche UK, USA, China
NCT02542293 Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
Non Small Cell Lung Carcinoma NSCLC
 Phase 3 Active, closed AstraZeneca UK, USA, India, China
NCT03003962 Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
Non Small Cell Lung Carcinoma NSCLC
 Phase 3 Active, closed AstraZeneca USA, China
NCT03164616 Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (ClinicalTrials.gov ↗)
Non Small Cell Lung Cancer NSCLC
 Phase 3 Active, closed AstraZeneca UK, USA, China
NCT03425643 Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) (ClinicalTrials.gov ↗)
Non-small Cell Lung Cancer
 Phase 3 Active, closed Merck Sharp & Dohme LLC Ireland, UK, USA, China
NCT03456076 A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer (ClinicalTrials.gov ↗)
Carcinoma, Non-Small-Cell Lung
 Phase 3 Active, closed Hoffmann-La Roche UK, USA, China
NCT03768063 A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (ClinicalTrials.gov ↗)
Cancer
 Phase 3 Active, closed Hoffmann-La Roche USA
NCT03800134 A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer (ClinicalTrials.gov ↗)
Non-Small Cell Lung Cancer
 Phase 3 Active, closed AstraZeneca USA, India, China
NCT04008030 A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
Metastatic Colorectal Cancer
 Phase 3 Active, closed Bristol-Myers Squibb Ireland, UK, USA, China
NCT04025879 A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
 Phase 3 Active, closed Bristol-Myers Squibb Ireland, UK, USA, China
NCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations (ClinicalTrials.gov ↗)
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
 Phase 3 Active, closed Takeda UK, USA, China
NCT04194944 A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
 Phase 3 Active, closed Eli Lilly and Company UK, China
NCT04351555 A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer (ClinicalTrials.gov ↗)
Non-Small Cell Lung Cancer
 Phase 3 Active, closed AstraZeneca UK, USA, India, China
NCT04380636 Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) (ClinicalTrials.gov ↗)
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
 Phase 3 Active, closed Merck Sharp & Dohme LLC UK, USA, China
NCT04538664 A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions (ClinicalTrials.gov ↗)
Carcinoma, Non-Small-Cell Lung
 Phase 3 Active, closed Janssen Research & Development, LLC UK, USA, India, China
NCT04590963 Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
Squamous Cell Carcinoma of the Head and Neck
 Phase 3 Active, closed AstraZeneca UK, USA
NCT04607421 A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (ClinicalTrials.gov ↗)
Neoplasms
 Phase 3 Active, closed Pfizer UK, USA, India, China
NCT04695925 Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations (ClinicalTrials.gov ↗)
Non-small Cell Carcinoma, EGFR Gene Mutation
 Phase 3 Active, closed Li Zhang, MD China
NCT04793958 Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Advanced Colorectal Cancer, Metastatic Colorectal Cancer
 Phase 3 Active, closed Mirati Therapeutics Inc. Ireland, UK, USA, China
NCT04956692 Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) (ClinicalTrials.gov ↗)
Non-Small Cell Lung Cancer
 Phase 3 Active, closed Merck Sharp & Dohme LLC USA
NCT04988295 A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
Carcinoma, Non-Small-Cell Lung
 Phase 3 Active, closed Janssen Research & Development, LLC UK, USA, India, China
NCT05048797 A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations (ClinicalTrials.gov ↗)
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
 Phase 3 Active, closed AstraZeneca USA, India, China
NCT05059522 Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing (ClinicalTrials.gov ↗)
Advanced Malignancies, NSCLC, Ovarian Cancer
 Phase 3 Active, closed Pfizer UK, USA
NCT05112965 An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) (ClinicalTrials.gov ↗)
Neoplasms
 Phase 3 Active, closed Hoffmann-La Roche China
NCT05116462 Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer (ClinicalTrials.gov ↗)
Non-Small Cell Lung Cancer
 Phase 3 Active, closed Innovent Biologics (Suzhou) Co. Ltd. China
NCT05261399 Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment (ClinicalTrials.gov ↗)
Carcinoma, Non-Small-Cell Lung
 Phase 3 Active, closed AstraZeneca UK, USA, China
NCT05502237 Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (ClinicalTrials.gov ↗)
Non-small Cell Lung Cancer
 Phase 3 Active, closed Gilead Sciences UK, USA, China
NCT05555732 Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) (ClinicalTrials.gov ↗)
Metastatic Non Small Cell Lung Cancer
 Phase 3 Active, closed Daiichi Sankyo UK, USA, China
NCT05668988 A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) (ClinicalTrials.gov ↗)
Non-small Cell Lung Cancer
 Phase 3 Active, closed Dizal Pharmaceuticals USA, China
NCT05687266 Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (ClinicalTrials.gov ↗)
NSCLC
 Phase 3 Active, closed AstraZeneca UK, USA, India, China
NCT05722015 A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
Metastatic Non-small Cell Lung Cancer
 Phase 3 Active, closed Merck Sharp & Dohme LLC USA, China
NCT05870319 A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients (ClinicalTrials.gov ↗)
Non-small Cell Lung Cancer
 Phase 3 Active, closed Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. China
NCT05984277 A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. (ClinicalTrials.gov ↗)
Metastatic Non-small Cell Lung Cancer
 Phase 3 Active, closed AstraZeneca UK, USA, India, China
NCT06074588 Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) (ClinicalTrials.gov ↗)
Non-small Cell Lung Cancer (NSCLC)
 Phase 3 Active, closed Merck Sharp & Dohme LLC UK, USA, China
NCT06097728 MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (ClinicalTrials.gov ↗)
Unresectable Pleural Mesothelioma
 Phase 3 Active, closed AstraZeneca UK, USA, China
NCT06151574 Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment (ClinicalTrials.gov ↗)
Lung Cancer, Non-squamous, Non-small Cell
 Phase 3 Active, closed Boehringer Ingelheim UK, USA, China
NCT06305754 Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (ClinicalTrials.gov ↗)
Non-small Cell Lung Cancer (NSCLC)
 Phase 3 Active, closed Merck Sharp & Dohme LLC USA, India, China
NCT06459180 A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Cervical Cancer
 Phase 3 Active, closed Merck Sharp & Dohme LLC Ireland, UK, USA, China
NCT06564844 A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features (ClinicalTrials.gov ↗)
Non-small Cell Lung Cancer
 Phase 3 Active, closed AstraZeneca USA
NCT06726265 Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
 Phase 3 Active, closed Immutep S.A.S. Ireland, UK, USA, India
NCT03178552 A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
 Phase 2/3 Active, closed Hoffmann-La Roche USA, China
NCT03391843 Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer (ClinicalTrials.gov ↗)
Rectal Cancer Stage III
 Phase 2 Active, closed RenJi Hospital China
NCT03775486 Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
Non-small Cell Lung Cancer NSCLC
 Phase 2 Active, closed AstraZeneca UK, USA, India
NCT03944772 Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (ClinicalTrials.gov ↗)
Non-Small Cell Lung Cancer
 Phase 2 Active, closed AstraZeneca USA
NCT04736173 Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer
 Phase 2 Active, closed Arcus Biosciences, Inc. USA
NCT04736823 A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC (ClinicalTrials.gov ↗)
NSCLC
 Phase 2 Active, closed Akeso China
NCT05217446 A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer (ClinicalTrials.gov ↗)
Metastatic Colorectal Cancer
 Phase 2 Active, closed Pfizer UK, USA
NCT05226871 Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
Breast Cancer, Head and Neck Cancer
 Phase 2 Active, closed Pfizer USA, China
NCT05633667 Study of Novel Treatment Combinations in Patients With Lung Cancer (ClinicalTrials.gov ↗)
Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
 Phase 2 Active, closed Gilead Sciences UK, USA
NCT05635708 A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (ClinicalTrials.gov ↗)
Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
 Phase 2 Active, closed BeiGene USA, China
NCT05751187 Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients (ClinicalTrials.gov ↗)
Non-squamous NSCLC
 Phase 2 Active, closed Shanghai Chest Hospital China
NCT05756972 A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC (ClinicalTrials.gov ↗)
NSCLC
 Phase 2 Active, closed Biotheus Inc. China
NCT06008093 A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (ClinicalTrials.gov ↗)
Carcinoma, Non-Small-Cell Lung
 Phase 2 Active, closed AstraZeneca USA
NCT06194448 To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations (ClinicalTrials.gov ↗)
Lung Cancer
 Phase 2 Active, closed AstraZeneca USA, China
NCT06246110 A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
NSCLC
 Phase 2 Active, closed Eikon Therapeutics USA
NCT06508606 AK117 (Anti-CD47 mAb) Plus Cetuximab or AK104 (Anti-PD-1/CTLA-4 bsAb) as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (ClinicalTrials.gov ↗)
Head and Neck Squamous Cell Carcinoma
 Phase 2 Active, closed West China Hospital China
NCT06946797 A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) (ClinicalTrials.gov ↗)
Non-Small Cell Lung Cancer
 Phase 2 Active, closed Bristol-Myers Squibb USA
NCT07005336 A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer (ClinicalTrials.gov ↗)
Non Small Cell Lung Cancer
 Phase 2 Active, closed TJ Biopharma Co., Ltd. China
NCT02671435 A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (ClinicalTrials.gov ↗)
Advanced Solid Tumors
 Phase 1/2 Active, closed MedImmune LLC UK, USA
NCT03785249 Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 (ClinicalTrials.gov ↗)
Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
 Phase 1/2 Active, closed Mirati Therapeutics Inc. USA
NCT04083599 GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
 Phase 1/2 Active, closed Genmab UK, USA, China
NCT04956640 Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) (ClinicalTrials.gov ↗)
Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms
 Phase 1/2 Active, closed Eli Lilly and Company USA
NCT05180799 A Phase 1/2 Study of BA3071 in Patients With Solid Tumors (ClinicalTrials.gov ↗)
NSCLC, Melanoma
 Phase 1/2 Active, closed BioAtla, Inc. USA
NCT05358249 Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (ClinicalTrials.gov ↗)
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung
 Phase 1/2 Active, closed Novartis Pharmaceuticals USA
NCT05904379 AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer (ClinicalTrials.gov ↗)
Advanced Non-small-cell Lung Cancer
 Phase 1/2 Active, closed Akeso China
NCT06762080 Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis (ClinicalTrials.gov ↗)
Leptomeningeal Metastasis
 Phase 1/2 Active, closed Guangzhou Medical University China
NCT06771622 Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors (ClinicalTrials.gov ↗)
Solid Cancer
 Phase 1/2 Active, closed FBD Biologics Limited China
NCT06809530 Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis (ClinicalTrials.gov ↗)
Leptomeningeal Metastasis, Pemetrexed, PD-1 Inhibitor
 Phase 1/2 Active, closed Guangzhou Medical University China
NCT02609776 Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (ClinicalTrials.gov ↗)
Non-Small-Cell Lung Cancer
 Phase 1 Active, closed Janssen Research & Development, LLC UK, USA, China
NCT02817633 A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) (ClinicalTrials.gov ↗)
Neoplasms
 Phase 1 Active, closed Tesaro, Inc. USA
NCT03530397 A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors (ClinicalTrials.gov ↗)
Selected Advanced Solid Tumors
 Phase 1 Active, closed MedImmune LLC USA
NCT03819465 A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
Metastatic Non-Small Cell Lung Cancer (NSCLC)
 Phase 1 Active, closed AstraZeneca USA
NCT04077463 A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (ClinicalTrials.gov ↗)
Carcinoma, Non-Small-Cell Lung
 Phase 1 Active, closed Janssen Research & Development, LLC USA, China
NCT04328844 A Study to Assess a PI3Kฮด Inhibitor (IOA-244) in Patients With Metastatic Cancers
Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult, NSCLC
 Phase 1 Active, closed iOnctura UK
NCT04449874 A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation (ClinicalTrials.gov ↗)
Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
 Phase 1 Active, closed Genentech, Inc. UK, USA
NCT04485013 TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers (ClinicalTrials.gov ↗)
Cancer
 Phase 1 Active, closed Tizona Therapeutics, Inc USA
NCT05117476 A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (ClinicalTrials.gov ↗)
Advanced Solid Tumor, NSCLC
 Phase 1 Active, closed Cullinan Therapeutics Inc. USA
NCT05355701 A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (ClinicalTrials.gov ↗)
Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer
 Phase 1 Active, closed Pfizer USA
NCT06333951 Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). (ClinicalTrials.gov ↗)
Thoracic Tumors, Non-small Cell Lung Cancer
 Phase 1 Active, closed Amgen USA, China
NCT06607185 A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors (ClinicalTrials.gov ↗)
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
 Phase 1 Active, closed Eli Lilly and Company USA
NCT06806852 A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone (ClinicalTrials.gov ↗)
Head and Neck Squamous Cell Carcinoma
 Phase 1 Active, closed Boehringer Ingelheim UK, USA
NCT06818812 A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (ClinicalTrials.gov ↗)
Solid Tumors
 Phase 1 Active, closed Incyte Corporation USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

194 conditions
Condition (as registered)Trials
Non-Small Cell Lung Cancer24
Non-small Cell Lung Cancer19
NSCLC16
Carcinoma, Non-Small-Cell Lung15
Colorectal Cancer12
Advanced Solid Tumors9
Pancreatic Ductal Adenocarcinoma7
Advanced Solid Tumor7
Leptomeningeal Metastasis7
Solid Tumors6
Non Small Cell Lung Cancer6
Non-small Cell Lung Cancer (NSCLC)6
Lung Cancer6
Solid Tumor5
PDAC - Pancreatic Ductal Adenocarcinoma5
Metastatic Colorectal Cancer4
Colorectal Neoplasms4
Head and Neck Cancer4
Neoplasms4
Pancreatic Cancer4
Cancer4
PDAC4
Colorectal Cancer (CRC)4
Melanoma4
Metastatic Non-small Cell Lung Cancer4
Head and Neck Squamous Cell Carcinoma3
CRC (Colorectal Cancer)3
Pancreatic Ductal Adenocarcinoma (PDAC)3
Non-Small-Cell Lung Cancer3
Colorectal Cancer Metastatic3
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)3
Non-squamous Non-small Cell Lung Cancer3
Advanced Colorectal Cancer2
Squamous Cell Carcinoma of the Head and Neck2
Rectal Adenocarcinoma2
Metastatic Solid Tumors2
Recurrent Head and Neck Squamous Cell Carcinoma2
Breast Cancer2
NSCLC (Non-small Cell Lung Cancer)2
Solid Tumor, Adult2

+ 154 more conditions in the trial records above.

03

Sponsors

lead sponsor per trial
Lead sponsorTrials
AstraZeneca22
Merck Sharp & Dohme LLC19
Bristol-Myers Squibb12
Revolution Medicines, Inc.10
Janssen Research & Development, LLC8
Hoffmann-La Roche8
Eli Lilly and Company6
Pfizer6
Guangzhou Medical University5
Mirati Therapeutics Inc.4
Incyte Corporation3
Boehringer Ingelheim3
Verastem, Inc.3
Tianjin Medical University Cancer Institute and Hospital3
Sun Yat-sen University3
Akeso3
AbbVie3
Gilead Sciences3
MedImmune LLC2
PAQ Therapeutics, Inc.2
Fate Therapeutics2
Genmab2
Novartis Pharmaceuticals2
Fudan University2
Haisco Pharmaceutical Group Co., Ltd.2
Fujian Cancer Hospital2
HC Biopharma Inc.2
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology2
West China Hospital2
Daiichi Sankyo2
Inhibrx Biosciences, Inc2
Eikon Therapeutics2
Shanghai Chest Hospital2
Sichuan Baili Pharmaceutical Co., Ltd.2
Seagen, a wholly owned subsidiary of Pfizer1
Radiation Therapy Oncology Group1
Corbus Pharmaceuticals Inc.1
Johnson & Johnson Enterprise Innovation Inc.1
AVEO Pharmaceuticals, Inc.1
Genentech, Inc.1
GlaxoSmithKline1
Kumquat Biosciences Inc.1
Sanofi1
Chugai Pharmaceutical1
Alterome Therapeutics, Inc.1
Tizona Therapeutics, Inc1
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)1
Astellas Pharma Inc1
D3 Bio (Wuxi) Co., Ltd1
Second Affiliated Hospital, Zhejiang University, School of Medicine1
Lepu Biopharma Co., Ltd.1
RenJi Hospital1
Sixth Affiliated Hospital, Sun Yat-sen University1
Hansoh BioMedical R&D Company1
Jiang Feng1
Institut de Recherches Internationales Servier1
Genfleet Therapeutics (Shanghai) Inc.1
Guangdong Provincial People's Hospital1
Shanghai 6th People's Hospital1
Multitude Therapeutics Inc.1
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University1
Shanghai Changzheng Hospital1
Tao Zhang1
Shanghai Zhongshan Hospital1
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University1
Meng Qiu1
Suzhou Suncadia Biopharmaceuticals Co., Ltd.1
Ji Dongmei1
FBD Biologics Limited1
Eye & ENT Hospital of Fudan University1
Immutep S.A.S.1
Synthekine1
iOnctura1
Takeda1
BioNTech SE1
Ellipses Pharma1
Bayer1
Arcus Biosciences, Inc.1
CStone Pharmaceuticals1
Phanes Therapeutics1
Cullinan Therapeutics Inc.1
BeiGene1
Tesaro, Inc.1
BioAtla, Inc.1
Amgen1
MediLink Therapeutics (Suzhou) Co., Ltd.1
Dizal Pharmaceuticals1
Jiangsu Alphamab Biopharmaceuticals Co., Ltd1
Peking University Cancer Hospital & Institute1
Qilu Pharmaceutical Co., Ltd.1
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.1
Sichuan Cancer Hospital and Research Institute1
Suzhou Puhe Pharmaceutical Technology Co., LTD1
Shanghai JMT-Bio Inc.1
Shanghai Pulmonary Hospital, Shanghai, China1
TJ Biopharma Co., Ltd.1
Li Zhang, MD1
Shanghai Junshi Bioscience Co., Ltd.1
Sinocelltech Ltd.1
Xiangya Hospital of Central South University1
Guangzhou University of Traditional Chinese Medicine1
Shuanghu Yuan1
Shanghai Huaota Biopharmaceutical Co., Ltd.1
Zhejiang Cancer Hospital1
Jiangsu Aosaikang Pharmaceutical Co., Ltd.1
Avistone Biotechnology Co., Ltd.1
Qian Chu1
Biotheus Inc.1
Betta Pharmaceuticals Co., Ltd.1
Innovent Biologics (Suzhou) Co. Ltd.1
CSPC Megalith Biopharmaceutical Co.,Ltd.1
Hunan Province Tumor Hospital1
Chinese Academy of Medical Sciences1
04

Trials by country register

RegisterPemetrexed trials
Clinical trials in China162
Clinical trials in USA152
Clinical trials in UK72
Clinical trials in India24
Clinical trials in Ireland17

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how Pemetrexed works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Pemetrexed (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.